News Center_News Center_FUSEN PHARMACEUTICAL



Home
About us 
Company profile History Organizational Chart Culture Honors
News 
Company News Industry News Media Information
Products 
Category of heat clearing and detoxification Category of cardio cerebrovascular category Category of reducing blood pressure and sugar Category of tonifying Category of regulating qi Category of anti-anemia Category of antibacterial and anti-inflammatory Category of gastrointestinal tract Category of expectorant cough
Investor relations 
Company files Financial reports Company reports Share price and share documentations Investor relations
Join us
Contact us



Confirm

Cancel

Language

News

Fusen Pharmaceutical Stock code：1652.HK

Location:

Homepage

News Center

Fusen Pharmaceutical Co., Ltd. Flunarizine Hydrochloride Capsules passed the consistency evaluation of generic drugs

24 2023.05

At the 86th Drug Fair, we are a strong fan of Fusen Pharmaceutical!

24 2023.05

Two TCM research centers inaugurated in Hengqin Guangdong Macao deep cooperation zone

28 2022.06

Warmly congratulate Jiaheng pharmaceutical on its approval of the drug production license!

28 2022.06

Fusen pharmaceutical: metformin hydrochloride sustained release tablets passed the consistency evaluation

Fusen pharmaceutical metformin hydrochloride sustained-release tablets have successfully passed the evaluation of the consistency of quality and efficacy of generic drugs! Metformin Hydrochloride Sustained Release Tablets, a diabetes drug, has been approved by the State Administration for drug control. This product has successfully passed the quality and efficacy consistency evaluation of generic drugs, which is an authoritative recognition of the R & D capacity, production and quality management system and clinical efficacy of Fusen pharmaceutical, further highlights the product brand of Fusen pharmaceutical, helps to improve the market competitiveness of the drug, and accumulates valuable experience for the company's follow-up products to carry out generic drug consistency evaluation. ▲ notice of approval from the State Drug Administration Metformin Hydrochloride Tablets is the basic medicine for diabetes. It is used for diet and physical exercise to control type 2 diabetes patients with blood glucose inefficacy, especially obesity and hyperinsulinemia. As a first-line drug for the treatment of type II diabetes, metformin is often used in combination with other oral hypoglycemic agents. ▲ for medical professionals only Because of the superiority of metformin, it is listed as the first-line treatment for hypoglycemic treatment in the guidelines for prevention and treatment of type II diabetes, formulated by professional academic organizations both at home and abroad. As the holder of drug marketing license, Fusen pharmaceutical will not forget its original intention, forge ahead, strictly control the product quality, and constantly optimize the product layout, so that more drugs of Fusen pharmaceutical can benefit the majority of patients.

26 2022.04

Fusen pharmaceutical: metformin hydrochloride sustained release tablets passed the consistency evaluation

Jiaheng pharmaceutical was approved to set up a post doctoral research workstation sub station

Recently, the Department of human resources and social security of Guangdong Province issued a notice that the National Postdoctoral Management Committee approved Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Co., Ltd., a wholly-owned subsidiary of Fusen pharmaceutical, to set up a postdoctoral scientific research workstation branch. ▲ exhibition hall of Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Co., Ltd ▲ exhibition hall of Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Co., Ltd Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Co., Ltd. is a research and development subsidiary established by Fusen pharmaceutical in response to the national development strategy of traditional Chinese medicine. In order to enhance the independent research and development ability of traditional Chinese medicine, take the research and development of high-quality and effective traditional Chinese medicine as the main goal, and integrate the high-quality traditional Chinese medicine resources in the industry. ▲ Guangdong Macao science and Technology Industrial Park of traditional Chinese Medicine The company is located in Hengqin Guangdong Macao cooperative traditional Chinese medicine science and Technology Industrial Park. It is the first R & D platform settled in the industrial park and officially operated after the establishment of Hengqin Guangdong Macao deep cooperation zone. It is the supporting unit of the large variety cultivation sub center of traditional Chinese medicine of the national traditional Chinese medicine modernization engineering technology center. Its main business is the R & D of innovative traditional Chinese medicine and secondary development of traditional Chinese medicine, chemical medicine raw materials and preparations, light medicine and beauty products and great health products. This time, Jiaheng pharmaceutical was approved to set up a post doctoral research workstation sub station, which is an affirmation of Jiaheng pharmaceutical's technological innovation ability and R & D ability, creates conditions for the company's talent training and the improvement of technological innovation ability, is conducive to further promoting the company's cooperation with universities and scientific research institutes, is conducive to the introduction of high-end R & D talents, is conducive to further improving the company's independent R & D ability and realizing the landing and transformation of scientific research achievements, Promote the sustainable innovation and development of the company and continuously improve the core competitiveness of the company.

19 2022.04

Jiaheng pharmaceutical was approved to set up a post doctoral research workstation sub station

…

Home

About us

News

Products

Investor relations

Join us

WeChat